



GLAND PHARMA LIMITED

May 4, 2022

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Earnings Conference Call

In continuation to our intimation dated April 5, 2022, regarding the Earnings Call for Investors/Analysts, please find enclosed details of the Earnings Call for Investors/Analysts to be held on **Thursday, May 19, 2022 at 1830 hours (IST)**.

The transcript of the Earnings Call will be available on the Company's website.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer



EARNINGS CONFERENCE CALL

The Company will host an Earnings conference call on **May 19th 2022, at 18:30 hours (IST)**, during which the management team will discuss the financial performance and take questions. Audio record and Transcript of the conference call will be available at www.glandpharma.com.

| Earnings Conference Dial-In Information | |
|--|---|
| Diamond pass link | Click here to register |
| Universal Access | +91 22 6280 1516 +91 22 7115 8875 |
| National Toll Free | 1 800 120 1221 |
| International Toll-Free Number | USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448 |
| International Toll Number | USA + 1 3233868721 UK + 44 2034785524 Singapore + 65 31575746 Hong Kong + 852 30186877 |

Playback of the earnings call will be available after the end of the call on the following number:

| Dial-in Number | Access code | Replay Dates |
|--|--------------------|--|
| India (+91 22 71945757) Hong Kong (800965553) Singapore (8001012510) UK (8007563427) USA (18332898317) | 63414 | May 19 th 2022 till May 26 th 2022 |

Contact:

Sumanta Bajpayee
Vice President – Finance & Investor Relations
E- Mail: sumanta.bajpayee@glandpharma.com and investors@glandpharma.com